Jennifer is Chief Development Officer, Biologics at Cullinan.
Prior to joining Cullinan, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development. Jennifer was also a member of the Leadership Team at Jounce.
Previously, during her 10 year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the Oncology and Immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.
Jennifer received her B.A. in Biology from Princeton University and Ph.D from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.
What is Jennifer Michaelson's net worth?
The estimated net worth of Jennifer Michaelson is at least $781,880.40 as of January 6th, 2025. Dr. Michaelson owns 95,760 shares of Cullinan Therapeutics stock worth more than $781,880 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Michaelson may own. Learn More about Jennifer Michaelson's net worth.
How old is Jennifer Michaelson?
Dr. Michaelson is currently 57 years old. There are 6 older executives and no younger executives at Cullinan Therapeutics. The oldest executive at Cullinan Therapeutics is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Jennifer Michaelson's age.
How do I contact Jennifer Michaelson?
Has Jennifer Michaelson been buying or selling shares of Cullinan Therapeutics?
In the last ninety days, Jennifer Michaelson has sold $50,040.00 of Cullinan Therapeutics stock. Most recently, Jennifer Michaelson sold 4,000 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $12.51, for a transaction totalling $50,040.00. Following the completion of the sale, the insider now directly owns 95,760 shares of the company's stock, valued at $1,197,957.60. Learn More on Jennifer Michaelson's trading history.
Who are Cullinan Therapeutics' active insiders?
Are insiders buying or selling shares of Cullinan Therapeutics?
During the last twelve months, insiders at the sold shares 10 times. They sold a total of 120,006 shares worth more than $2,424,144.13. The most recent insider tranaction occured on February, 25th when insider Jeffrey Alan Jones sold 4,895 shares worth more than $41,754.35. Insiders at Cullinan Therapeutics own 6.1% of the company.
Learn More about insider trades at Cullinan Therapeutics. Information on this page was last updated on 2/25/2025.
